TRIPSTAR: Prioritizing oral triptan treatment attributes in migraine management

P. J. Goadsby, D. W. Dodick, M. D. Ferrari, D. C. McCrory, P. Williams

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Migraine can be associated with severe pain and is often very disabling. Optimal treatment should provide rapid and sustained, complete pain relief, be well tolerated and restore normal function. The seven commercially available triptans show differences in performance on individual treatment attributes. The TRIPSTAR multiattribute decision model compares the profiles of the oral triptans, using efficacy and tolerability data weighted for importance, to identify if measurable differences are clinically relevant. Application of the TRIPSTAR model was demonstrated at the Migraine Trust International Symposium 2002, where delegates collectively prioritized treatment attributes according to the needs of a specific patient case history. The TRIPSTAR model identified the preferred triptans for this patient. These three triptans, almotriptan 12.5 mg, eletriptan 80 mg and rizatriptan 10 mg, standout in a triptan meta-analysis, three TRIPSTAR surveys and in a demonstration of the TRIPSTAR model at a symposium in the USA. Taken together the findings suggest that some differences amongst triptans may be relevant in clinical practice.

Original languageEnglish (US)
Pages (from-to)137-143
Number of pages7
JournalActa neurologica Scandinavica
Issue number3
StatePublished - Sep 2004


  • Comparison
  • Ideal treatment
  • Migraine
  • Multiattribute model
  • Triptans

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'TRIPSTAR: Prioritizing oral triptan treatment attributes in migraine management'. Together they form a unique fingerprint.

Cite this